Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?

• Published in: Diabetes care Vol. 40; no. 7; pp. 813 - 820
• Main Authors: Abdul-Ghani, Muhammad, DeFronzo, Ralph A., Del Prato, Stefano, Chilton, Robert, Singh, Rajvir, Ryder, Robert E.J.
• Format: Journal Article
• Language: English
• Published: United States American Diabetes Association 01.07.2017
• Subjects: Animals; Benzhydryl Compounds - pharmacology; Benzhydryl Compounds - therapeutic use; Cardiovascular disease; Cardiovascular diseases; Cardiovascular Diseases - etiology; Cardiovascular Diseases - prevention & control; Cerebral infarction; Clinical trials; Complications; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; GLP-1 receptor agonists; Glucagon; Glucagon-like peptide 1; Glucagon-Like Peptides - pharmacology; Glucagon-Like Peptides - therapeutic use; Glucosides - pharmacology; Glucosides - therapeutic use; Heart diseases; Humans; Hyperglycemia; Hyperglycemia - complications; Hyperglycemia - drug therapy; Hypoglycemic Agents - therapeutic use; Liraglutide - pharmacology; Liraglutide - therapeutic use; Microvasculature; Mortality; Myocardial infarction; Patients; Peptides; Pioglitazone; Randomized Controlled Trials as Topic; Reagents; Reduction; Risk Factors; s in Care; Stroke; Thiazolidinediones - pharmacology; Thiazolidinediones - therapeutic use; Treatment Outcome

Hyperglycemia is the major risk factor for microvascular complications in patients with type 2 diabetes (T2D). However, cardiovascular disease (CVD) is the principal cause of death, and lowering HbA1c has only a modest effect on reducing CVD risk and mortality. The recently published LEADER and SUST...